Singapore markets closed

Evelo Biosciences, Inc. (EVLO)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.0435-0.0060 (-12.12%)
At close: 03:55PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.0495
Open0.0435
Bid0.0000 x 2900
Ask0.0000 x 1000
Day's range0.0435 - 0.0525
52-week range0.0280 - 13.9300
Volume22,122
Avg. volume33,335
Market cap939,652
Beta (5Y monthly)2.03
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis

    - Primary endpoint was not achieved – - Company exploring strategic alternatives and partnering opportunities for EDP1815 and its SINTAX platform - CAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO) (“Evelo” or the “Company”), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announced top-line results from its Phase 2 clinical study wit